Ovagen Overview, Dosing & Safety | Peptide Database

Ovagen (EDL)

EDL Tripeptide | Liver & GI Bioregulator

Community Research

Join others researching Ovagen — share findings, ask questions, and learn from real experiences

Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects.

Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.

Molecular Data

Glutamic Acid

Position 1

Aspartic Acid

Position 2

Leucine

Position 3

Research Indications

Reduces long-term fibrosis development in liver tissue.

Protects liver through gene expression regulation.

Helps protect GI mucosal layer from various insults.

May protect GI tract from antibiotic-induced damage.

Protects against environmental toxin effects on GI tract.

Addresses age-related liver changes through bioregulation.

Supports GI tract function during aging.

Dosing Protocols

Available in capsule form for oral administration. As a tripeptide, Ovagen is transported via PEPT1/PEPT2 transporters for targeted delivery to liver and GI tissue. Typical protocol involves 10-20 day cycles.

Standard protocol

10-20 mg

Daily for 10-20 days

Oral capsules

Maintenance

10 mg

2-3 cycles yearly

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Generally well-tolerated

Minimal side effects reported

Stop Signs - Discontinue if:

Allergic reactions

Unusual GI or liver symptoms

Contraindications

Active liver emergencies (seek medical care)

Known hypersensitivity

Pregnancy or breastfeeding

Quality Checklist

Good Signs

White powder or capsules

Clear solution if reconstituted

Proper packaging and labeling

Warning Signs

Unknown source or purity

Do not confuse with FSH derivative of same name

Bad Signs

Discoloration

Unusual odor

Damaged packaging

Frequently Asked Questions

How does Ovagen protect your gut from antibiotic damage?

Ovagen (EDL tripeptide) works by protecting the GI mucosal layer from antibiotic-induced damage. The peptide is transported via PEPT1/PEPT2 transporters directly to gut tissue where it regulates gene expression to strengthen mucosal integrity. Taking Ovagen during and after antibiotic courses may help preserve your microbiome.

Can I use Ovagen if I'm taking other Khavinson bioregulators?

Yes. Ovagen combines synergistically with Livagen, Epitalon, and other Khavinson peptides since they target different tissues. Many anti-aging protocols use multiple bioregulators together—Ovagen for liver/GI, Epitalon for telomeres, etc. Follow recommended cycling protocols to avoid overstimulation.

How long does it take Ovagen to reduce liver fibrosis?

Results are cumulative. During a 10-20 day cycle, gene expression changes begin immediately, but visible improvements in liver fibrosis occur over weeks to months with periodic cycles. The file recommends 2-3 cycles yearly for maintenance, suggesting ongoing use is needed for long-term fibrosis reduction.

Is Ovagen better taken as a capsule or injection?

Both routes work, but oral capsules are more convenient for daily dosing and room-temperature storage. Injectable forms offer direct absorption but require refrigeration and reconstitution. Choose based on your preference for convenience (capsules) vs. guaranteed absorption (injection).

References

Ovagen (EDL) is a tripeptide bioregulator with effects on liver and GI tract.

Di- and tripeptides are transported via PEPT1/PEPT2, explaining tissue-specific targeting.

Short peptides reduce long-term fibrosis in liver tissue through gene expression regulation.

Related Peptides

Complementary liver bioregulators with different sequences and mechanisms.

Both support liver health through different pathways.

Often combined in comprehensive anti-aging Khavinson protocols.

Both support GI health; different mechanisms.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.